Connect with us


AstraZeneca to Acquire CinCor Pharma for Over $1 Billion

AstraZeneca has agreed to acquire CinCor Pharma in a deal that could exceed $1 billion. CinCor Pharma develops treatments for resistant hypertension and chronic kidney disease, and the acquisition will strengthen AstraZeneca’s cardiorenal pipeline by adding CinCor’s drug candidate baxdrostat, an aldosterone synthase inhibitor.



AstraZeneca has signed a definitive agreement to acquire CinCor Pharma, a clinical-stage US biopharmaceutical company focused on developing new treatments for resistant and uncontrolled hypertension and chronic kidney disease. The value of the transaction may exceed one billion dollars, as reported by AstraZeneca in a statement.

The acquisition will strengthen AstraZeneca’s cardiorenal pipeline by adding CinCor’s drug candidate baxdrostat, an aldosterone synthase inhibitor (ASI) for lowering blood pressure in refractory hypertension.

Baxdrostat represents a next-generation ASI that is highly selective for aldosterone synthase and bypasses the cortisol pathway in humans. The opportunity also provides the potential for combination with Farxiga and complements  AstraZeneca’s strategy to provide additional benefits in cardiorenal disease, where there is a high unmet medical need.

Read more about the acquisition of CinCor Pharma by AstraZeneca and find other important news in the biotech sector and not only with our companion app.Born2Invest’s team of journalists gathers the most interesting business news in a single mobile application. It’s impossible to keep up with everything you’re interested in, but our companion app will help you keep track of the important news. Our app is being updated throughout the day.

AstraZeneca closed the first nine months of 2022 with a profit of $2.4 billion

AstraZeneca will initiate a tender offer to acquire all of CinCor’s outstanding shares for a price of $26 per share in cash at closing, plus a non-tradable contingent value right of $10 per share in cash. 

The upfront cash portion of the consideration represents a transaction value of approximately $1.3 billion and a 121% premium over CinCor’s closing market price on January 6, 2023. Combined, the potential contingent value payments maximum and upfront represent, if achieved, a transaction value of approximately $1.8 billion.

Mene Pangalos, vice president of AstraZeneca’s biopharmaceuticals, comments that “the acquisition of CinCor supports our commitment to cardiorenal diseases and further strengthens our portfolio with baxdrostat.”

Marc de Garidel, CEO of CinCor, highlights that “we are excited about the proposed acquisition of CinCor Pharma by AstraZeneca, as we believe it offers the prospect of accelerating the development schedule and expanding the range of benefits that patients with cardiorenal diseases could get”.

AstraZeneca closed the first nine months of 2022 with a profit of $2.4 billion, which means multiplying the profit for the same period of 2021 by five, according to the latest quarterly results published by the company. The multinational justifies this result by the success of its cancer treatments.

The company’s turnover increased by 30% between January and September 2022 compared to the same period in 2021, up to $33.1 billion. Sales improved due to the incorporation of the Alexion company.


(Featured image by stevepb via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.